Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients [Yahoo! Finance]
Athira Pharma, Inc. (ATHA)
Company Research
Source: Yahoo! Finance
Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD's primary endpoint, the Global Statistical Test, designed to measure overall impact on disease Webinar event on Tuesday, June 18 th at 11:30 a.m. ET BOTHELL, Wash., June 12, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will host a webinar event with key opinion leaders to discuss the unmet medical need and the potential opportunity for fosgonimeton to improve cognition and function in mild-to-moderate Alzheimer's disease. The event titled, “Lead Up to LIFT-AD Readout: Understanding the Primary Endpoint and Continued Need for Effective New Treatments in Alzheimer's Disease,” will take place on Tuesday, June 18th, 2024, beginning at 11:30 a.m. ET. “With the Phase 2/3 LIFT-AD study expected to report topline data in the second h
Show less
Read more
Impact Snapshot
Event Time:
ATHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHA alerts
High impacting Athira Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATHA
News
- Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $5.00.MarketBeat
- Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative DiseasesGlobeNewswire
- Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks [Yahoo! Finance]Yahoo! Finance
- Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Rodman & Renshaw from a "buy" rating to a "neutral" rating.MarketBeat
- Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
ATHA
Earnings
- 5/15/24 - Beat
ATHA
Sec Filings
- 9/17/24 - Form 8-K
- 9/5/24 - Form 144
- 9/5/24 - Form 4
- ATHA's page on the SEC website